Asimov vs Tempus

Side-by-side comparison of AI visibility scores, market position, and capabilities

Tempus leads in AI visibility (74 vs 36)
Asimov logo

Asimov

EmergingLife Sciences & BioTech

Mammalian Cell Engineering Platform for Biologics & Gene Therapy

Asimov develops software and AI tools for mammalian cell engineering to accelerate design and manufacturing of biologics and gene therapies; combines synthetic biology, biophysical simulation, and machine learning;

AI VisibilityBeta
Overall Score
D36
Category Rank
#116 of 198
AI Consensus
70%
Trend
stable
Per Platform
ChatGPT
32
Perplexity
42
Gemini
37

About

Asimov is a Boston-based biotechnology and computational biology company founded in 2017 by Alec Nielsen, Raja Srinivas, and Christopher Voigt. The company's mission is to apply software engineering principles to cell engineering — treating genetic circuits in mammalian cells the way software engineers treat code. Asimov builds computational tools and AI models that predict how genetic constructs will behave in mammalian cells, enabling researchers to design, simulate, and optimize biologics and gene therapy vectors before conducting expensive wet lab experiments.

Full profile
Tempus logo

Tempus

LeaderLife Sciences & BioTech

AI-Enabled Precision Medicine

Publicly traded AI precision medicine company (Nasdaq: TEM); $1.27B revenue in 2025 (+83% YoY); $14B+ market cap; genomic profiling, algorithmic diagnostics, and clinical trial matching across oncology, neurology, and cardiology.

AI VisibilityBeta
Overall Score
B74
Category Rank
#11 of 198
AI Consensus
68%
Trend
stable
Per Platform
ChatGPT
71
Perplexity
68
Gemini
80

About

Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder of Groupon) and headquartered in Chicago, Illinois, Tempus built the world's largest library of clinical and molecular data and applies AI to help physicians make more personalized, data-driven treatment decisions. The company's core offerings include genomic profiling (sequencing tumor DNA to identify mutations and actionable targets), algorithmic diagnostic tests (AI-driven companion diagnostics for cancer treatment selection), clinical trial matching (connecting eligible patients to appropriate studies), and data licensing to pharmaceutical and biotech partners for drug discovery and clinical development.

Full profile

AI Visibility Head-to-Head

36
Overall Score
74
#116
Category Rank
#11
70
AI Consensus
68
stable
Trend
stable
32
ChatGPT
71
42
Perplexity
68
37
Gemini
80
31
Claude
77
41
Grok
69

Key Details

Category
Mammalian Cell Engineering Platform for Biologics & Gene Therapy
AI-Enabled Precision Medicine
Tier
Emerging
Leader
Entity Type
brand
brand

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.